FY2025 Earnings Estimate for MaxCyte Issued By William Blair

MaxCyte, Inc. (NASDAQ:MXCT) – Research analysts at William Blair raised their FY2025 earnings estimates for shares of MaxCyte in a research report issued on Thursday, November 13th. William Blair analyst M. Larew now anticipates that the company will post earnings of ($0.39) per share for the year, up from their previous forecast of ($0.46). William Blair has a “Market Perform” rating on the stock. The consensus estimate for MaxCyte’s current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte’s Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.27) EPS.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The business had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%.

A number of other research firms have also issued reports on MXCT. Stephens started coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $6.00 price target for the company. BTIG Research reiterated a “neutral” rating on shares of MaxCyte in a research report on Monday, August 11th. Wall Street Zen lowered shares of MaxCyte from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Monday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, MaxCyte presently has an average rating of “Hold” and an average target price of $7.00.

MaxCyte Trading Up 4.9%

Shares of MaxCyte stock opened at $1.71 on Monday. MaxCyte has a 1 year low of $1.26 and a 1 year high of $5.20. The company has a market cap of $182.30 million, a P/E ratio of -3.98 and a beta of 1.23. The stock has a 50-day moving average price of $1.59 and a 200 day moving average price of $1.86.

Hedge Funds Weigh In On MaxCyte

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd boosted its stake in shares of MaxCyte by 122.8% during the 3rd quarter. XTX Topco Ltd now owns 389,071 shares of the company’s stock worth $615,000 after acquiring an additional 214,405 shares in the last quarter. Mirabella Financial Services LLP boosted its position in MaxCyte by 24.2% during the third quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock worth $12,956,000 after purchasing an additional 1,600,000 shares during the period. Bridgeway Capital Management LLC grew its holdings in MaxCyte by 44.6% during the third quarter. Bridgeway Capital Management LLC now owns 180,800 shares of the company’s stock valued at $286,000 after purchasing an additional 55,800 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in MaxCyte during the third quarter valued at approximately $3,330,000. Finally, UBS Group AG raised its position in shares of MaxCyte by 186.3% in the third quarter. UBS Group AG now owns 474,487 shares of the company’s stock valued at $750,000 after purchasing an additional 308,769 shares during the period. 68.81% of the stock is currently owned by institutional investors.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.